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hemostasis assays
Jonathan Douxfils1, Anne Tamigniau2, Bernard Chatelain2, Catherine Goffinet3, Jean-Michel Dogné1
and François Mullier1,2*Abstract
Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular
weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment of
thromboembolic diseases. However, these agents are associated with limitations, such as the need for regular
coagulation monitoring (VKAs and UFH) or a parenteral route of administration (UFH, LMWHs and fondaparinux).
Several non-VKA oral anticoagulants (NOACs) are now widely used in the prevention and treatment of thromboembolic
diseases and in stroke prevention in non-valvular atrial fibrillation. Unlike VKAs, NOACs exhibit predictable
pharmacokinetics and pharmacodynamics. They are therefore usually given at fixed doses without routine
coagulation monitoring. However, in certain patient populations or special clinical circumstances, measurement
of drug exposure may be useful, such as in suspected overdose, in patients experiencing a hemorrhagic or
thromboembolic event during the treatment’s period, in those with acute renal failure, in patients who require
urgent surgery or in case of an invasive procedure. This article aims at providing guidance on laboratory testing
of classic anticoagulants and NOACs.
Keywords: Vitamin K antagonist, Dabigatran, Rivaroxaban, Apixaban, Low molecular weight heparin, Enoxaparin,
Monitoring, Non-VKA oral anticoagulantsIntroduction
Anticoagulants are a mainstay of cardiovascular therapy
and, until recently, vitamin K antagonists (VKAs) were
the only oral anticoagulants available. The knowledge
about monitoring and dosing of VKAs in order to
maximize their efficacy and minimize hemorrhagic
complications has increased considerably since their
introduction in 1950s. In addition, the management of
VKAs has been optimized with the establishment of
anticoagulation clinics, as well as self-monitoring and
self-management programs. However, VKAs have still* Correspondence: mullierfrancois@gmail.com
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unless otherwise stated.strong limitations such as a slow onset and offset of
action, the requirement of variable dose regimen, a
series of multiple drug-drug interactions and a consider-
able inter-individual variability. These limitations make
coagulation monitoring and frequent dose adjustments
necessary to ensure an adequate level of anticoagulation.
Unfractionated heparin (UFH) and low molecular weight
heparins (LMWHs) are also a cornerstone in the arma-
mentarium of anticoagulation. While UFH has to be mon-
itored closely due to unspecified bindings to proteins,
endothelial cells and macrophages conducing to a variable
response from patient to patient, the interest of monitoring
LMWHs is controversial but suggested in specific situations
such as in extreme body weights, severe renal insufficiency,
pregnancy and cirrhosis.
Non-VKA oral anticoagulants (NOACs) have major
pharmacologic advantages over VKAs, including a rapid
onset/offset of action, fewer drug interactions, and pre-
dictable pharmacokinetics, eliminating theoretically thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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agencies have approved NOACs for various indications
based on the results of large phase-III clinical trials
demonstrating the efficacy and safety of these compounds.
Effectively, they were found at least as efficacious, if not
better, than warfarin in the setting of stroke prevention in
adult patients with non-valvular atrial fibrillation (NVAF)
[1-4] and in the treatment and the secondary preven-
tion of venous thromboembolism [5-9]. Compared to
LMWHs, these agents also proved their non-inferiority
or superiority for initial treatment of venous thrombo-
embolism and for thromboprophylaxis in patients under-
going hip or knee arthroplasty, [10-20]. Non-VKA oral
anticoagulants will certainly replace some of the trad-
itional anticoagulants in the future but it is important to
keep in mind that the introduction of these new agents
will also change the strategies of patient management and
of the hospital routine [21]. Therefore, the knowing of the
pharmacology and the impact of these new compounds
on routinely used coagulation assays is of great import-
ance to achieve optimal patient outcomes. Moreover, it is
anticipated that a non-negligible proportion of patients
will reach either insufficient or supra-therapeutic level
when given at fixed dose leading to the introduction of
dedicated coagulation tests that respond faithfully to the
pharmacodynamics of NOACs.
The aim of this review is to define why, when and how
to measure traditional anticoagulant and NOACs.
Pre-treatment biological screening
The following information should be collected before
prescribing an anticoagulant at therapeutic or prophylactic
dose: cell blood count, prothrombin time (PT), activated
partial thromboplastin time (aPTT) and renal function.
Platelet count should be performed before and during
follow-up of UFH or LMWH treated patients to screen
for immune heparin-induced thrombocytopenia [22,23].
In clinical trials of oral anticoagulants, drug eligibility
and dosing were determined using the Cockcroft-Gault
equation to estimate creatinine clearance (CRCL) as a
measure of renal function. Importantly, it was proved
that the use of modification of diet in renal disease
(MDRD)-derived estimated glomerular filtration rate
(eGFR) instead of Cockcroft-Gault in prescribing anti-
coagulants leads to overestimation of renal function in
lower values [24-26]. Thus, many elderly patients would
either incorrectly become eligible for them or would
receive a too high a dose.
Samples acquisition, processing and storage
Sample acquisition and processing are of great importance
since it was proven that each component of the specimen
collection system (needle gauge, composition of the collect-
ing tube, concentration of sodium citrate) may potentiallyimpact the results for coagulation testing [27]. This
should be performed according to international recom-
mendations [27].
For example, contamination of the citrate solution by
divalent ion such as magnesium influences PT [28].
For UFH and LMWH monitoring, there is a risk of
platelet activation between sampling and centrifugation
that leads to neutralization of heparin by binding to PF4
and underestimation of anti-Xa activity. If sampling is
performed in citrated tubes, it is important that the
delay between sampling and centrifugation is lower than
1 hour and thus to warn the laboratory before sampling.
The sample should also be tested within 4 hours [29]
The sample may also be collected in a mixture of citrate
109 mM, theophylline, adenosine and dipyridamole
(CTAD) which allows increasing the acceptable delay
between sampling and centrifugation to 4 hours [30,31].
Heparin is lost more rapidly in citrate tubes that contain
a large air space (after addition of blood) due to accelerated
platelet activation and release of PF4. This effect is sup-
pressed if CTAD is used [32].
Biological monitoring of anticoagulant treatments
Vitamin K antagonists
Vitamin K antagonists produce their anticoagulant effect
by interfering with the cyclic regeneration of vitamin K
from the oxidized form to the reduced form. This is
achieved by inhibiting the vitamin K epoxyde-reductase.
Reduced vitamin K is necessary for the γ-carboxylation
of glutamate residues of factors II, VII, IX, X, protein
C, S and Z. These compounds are also known for their
highly unpredictable pharmacokinetics and pharmaco-
dynamics from patient to patient, their narrow thera-
peutic range, as well as for their numerous interactions
with food and drugs [33,34]. There is hence a real need
for monitoring those treatments in order to ensure their
efficacy and to minimize hemorrhagic complications.
Prothrombin time
The PT has been widely used to monitor patients under
VKA. It is based on adding thromboplastin, a substitute
of endogenous tissue factor (TF), and calcium to citrated
decalcified platelet poor plasma (PPP), in order to gener-
ate fibrin clot formation [35]. Various factors are to be
considered when interpreting results of PT, such as the
composition of thromboplastin and the coagulometer
(optical or mechanical detection) used for its determin-
ation. Thromboplastin reagents are usually made of TF,
phospholipids, calcium, and often contain an inhibitor of
heparin such as polybrene. The two most common
sources of TF are rabbit brain and human recombinant
preparations. Lupus anticoagulant or hematocrit may also
influence the PT. When introducing a novel thromboplas-
tin reagent made of relipidated tissue factor, responsiveness
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patients under VKA with this reagent.
Before 1980, clotting time was usually expressed in
seconds or as a ratio compared to a reference value. This
way of expressing results didn’t enable to compare results
obtained from different laboratories or determined with
different reagents or coagulometers. In 1983, the World
Health Organization (WHO) developed the International
Normalized Ratio (INR) to standardize the expression of
PT for patients under VKA. This way of expressing PT is
based on determining the International Sensitivity Index
(ISI) of the laboratory thromboplastin compared to an
International Reference Preparation (IRP) for which the
responsiveness to VKA is known. Depending on the origin
of the tissue factor, various IRP are available such as
WHO human IRP rTF/95 or ECAA (European Concerted
Action on Anticoagulation) rabbit reference reagent
EUTHR-1 [36]. Previously, TF was extracted from tissues
such as rabbit brain or bovine extracts but nowadays, re-
combinant human thromboplastins with international
sensitivity index (ISI) close to 1 have been designed and
are replacing progressively animal reagents.
INR ¼ PT patient
MNPT
 ISI
Log INR ¼ ISI Log PT ratioð Þ
Because of the numerous variables to be considered
when determining INR, each laboratory should determine
its own ISI locally. However, this procedure of local deter-
mination of ISI is quite labor intensive and time consum-
ing. It requires 60 patients stable under VKA and 20
healthy subjects. The reference technique is a manual one.
The ISI determination consists of comparing PT deter-
mined with IRP on manual technique to PT determined
by local coagulometer. Mean normal prothrombin time
(MNPT) corresponds to the geometric mean of the 20
healthy subjects. Because of the difficulty of the procedure
(e.g. the need for large numbers of normal and patients’
blood samples and the availability of reference thrombo-
plastins), ISI calibration is now rarely performed at local
hospital levels. Therefore, commercial calibrators with
certified INR have been released by manufacturers in
order to simplify the procedure and to validate the local
ISI. However, manufacturers’ ISIs and INRs may not
reflect local values as, for example, coagulometer cali-
bration ISIs are required and INRs often vary between
coagulometers even of the same model and manufacturer
used in the same laboratory [37]. Results with VKAs are
expected to be further improved by two recent European
Action on Anticoagulation (EAA) developments in rou-
tine oral anticoagulant control (i.e. simplified local INR
derivation with the PT/INR line and prediction of further
clinical events by a type of variance growth rate analysis),as demonstrated by a recent EAA multicenter study [38].
In the PT/INR Line method, local PT is plotted against 5
certified INR for plasma calibrators and ISI is then deter-
mined using the orthogonal regression [39]. Calibrators
used for this determination may be of two different types:
lyophilized or frozen plasma prepared from native patient
plasmas or plasmas prepared by artificial depletion (select-
ive adsorption) of vitamin K dependent clotting factors.
Those two types of calibrators aren’t commutable due to
different results [40]. The European Society of Cardiology
(ESC) Task Force on Anticoagulants has recently stated
that PT/INR Line achieves reliable INR without the need
for local ISI calibrations and thus recommended it. The
EAA PT/INR Line test plasmas are now available in a
five-plasma kit [28].
Recently, a variable growth rate (VGR) analysis was
shown in a EAA report published in 2013 to be of
greater value than the previously accepted ‘time in
INR range’, in predicting ‘clinical events’ during war-
farin treatment, particularly in short term oral anti-
coagulant [41].
Point of care devices
Point of care testing (POCT) has been developed for
whole-blood samples in order to permit monitoring in
an easier way, less invasive and more convenient for the
patient. POCT devices are submitted to the same level
of requirement for calibration and control as traditional
determination on citrated blood [42]. Practically, ac-
curacy and precision of point of care testing seem to
be sufficient and comparable to results obtained in a
laboratory setting [43]. Recent study revealed that point-
of-care patient self-testing at home achieves high-quality
warfarin therapy outside of clinical trials and compares
favorably with the results achieved in randomized trials
or in anticoagulation clinic settings [44]. A recent
meta-analysis show that time in therapeutic range
(TTR) increased by 5% for personal self-testing (PST)/
personal self-monitoring (PSM) compared with usual
laboratory-based monitoring [45]. In addition, a sig-
nificant reduction in the rate of thromboembolic com-
plications with PST/PSM was observed but not in the
rate of major bleeding or overall mortality compared
with usual laboratory-based INR monitoring. The fre-
quency of INR testing with PST/PSM is higher than
usual laboratory-based monitoring [46], leading to less
cost-effectiveness [47]. Based on the preceding consid-
erations, the 9th Edition of the American College of
Chest Physicians (ACCP) on the Antithrombotic Therapy
and Prevention of Thrombosis, makes a weak recommen-
dation in favor of PSM (not PST) for patients treated with
VKAs who are motivated and can demonstrate compe-
tency in self-management strategies, including the POC
equipment [48].
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At the start of treatment, several days or weeks may be
needed to reach steady state due to particularly long
VKA’s onset of action [49]. During this stabilization
period, frequent monitoring is recommended to adjust
dosing based on INR determination according to vali-
dated VKA dosing normograms [50] computer-assisted
oral anticoagulant dosage program [51]. In patients be-
ginning VKA therapy, INR monitoring should be started
after the initial two or three doses of oral anticoagula-
tion therapy [48]. In the hospital setting, INR monitor-
ing should be performed daily until the therapeutic
range has been reached for at least two consecutive days
[52]. In outstanding patients, starting their treatment,
monitoring may be reduced to once every few days until
the patient is stabilized at the therapeutic range [52].
For patients who are receiving a stable dose of oral anti-
coagulants, previous recommendations mention that
monitoring should be performed at an interval of no
longer than every 4 weeks (Grade 2C) [34]. More recent
recommendations advice intervals between controls
may be extended to 12 weeks for patients with optimal
adherence to treatment [52-55]. Patients more likely to
maintain stable anticoagulation are older (>70 years),
have an INR target of 2-3 (versus higher targets), and do
not have heart failure [55]. If adjustments to the dose
are required, then the cycle of more frequent monitor-
ing should be repeated until a stable dose response can
again be achieved [52].
Prompt repeat testing after out-of range INR value is
associated with better anticoagulation control (higher
TTR) and could be an important part of a quality im-
provement effort for oral anticoagulation [56]. The opti-
mal recall interval after a high (>4.0) or low (<1.5) INR
value is within 7 days, and within 14 days after a mildly
high (3.1 to 3.9) or mildly low (1.6 to 1.9) INR value
[45]. The 9th ACCP guidelines suggest for patients taking
warfarin with previously stable therapeutic INRs present-
ing with a single out-of-range INR within 0.5 units of the
range to continue the current dose and retest the INR
within 1 or 2 weeks (Grade 2C) [55]. This suggestion is
based on the concept that for patients with previously
stable INR control, the single mildly out-of-range INR
likely represents random variation and does not warrant a
change in VKA dose; too frequent VKA dose adjustments
tend to destabilize the INR leading to suboptimal control
[50]. Available evidence supports this recommendation for
patients presenting with an out of range INR where there
is no identifiable change in diet or medications to explain
the result. However, this recommendation should not take
the place of a thorough patient interview and individu-
alized assessment of the patients risk for bleeding and
thromboembolism. A one-time dose adjustment is rea-
sonable in the setting of a temporary, but not ongoing,precipitating factor for an out of range INR. A change
in maintenance dose is advisable if a precipitating fac-
tor is identified and will continue long term (e.g. a new
chronic medication or dietary habit) [55].
Recent studies found that different factors are associate
with an INR-stability in long-term management such as
age <70 years, the absence of chronic diseases, and male
gender while congestive heart failure, diabetes, and a tar-
get range for INR ≥3.0 were associated with instability
[57,58]. Therefore, in order to improve TTR, and thereby
improve patient outcomes, it is recommended to target
the INR of 2.5 and to avoid the explicit or implicit pursuit
of non-standard INR targets [59]. However, as discussed
above, a VGR analysis was shown to be of greater value
than the TTR in predicting clinical events [38,41].
Dietary consumption of vitamin K is also a factor that
influences the stability of the INR in patients treated by
VKA. Several studies had been performed to assess to
benefit of the supplementation in vitamin K in unstable
patients and it seems that vitamin K supplement improved
the stability of anticoagulant therapy [60-68]. Finally, for
patients with INR 4.5 to 10.0 and no symptoms of bleed-
ing, it’s recommended to skip 1 to 3 doses of VKA and
retest INR. For patients with INR >10.0, give 2.5 mg oral
vitamin K and retest INR next day [50].
Interpretation
Several therapeutic ranges have been proposed to assess
the therapeutic effects of VKA depending on the clinical
indications [28]. There is a significant increase in bleeding
risk for INR over 4.5 and thrombotic complications
should be considered for INR lower than 2.0 [28,69,70]. In
clinical studies, one should pay attention to the reliability
of the INR determination. For example, in the pivotal
trials comparing NOACs with warfarin, evidence of the
validation of the stated INR was not provided. In RE-LY
two important assessments of INR control (i.e. local ISI
calibration and external quality control of INR) were
not reported. This “claimed INR” makes cross-trial com-
parisons difficult [28,71]. In addition, Poller et al. hypothe-
sized that this may be one of the reasons explaining why
the EAA patients receiving warfarin suffered considerably
less thrombotic and bleeding episodes [38].
Heparins
Unfractionated heparin
The anticoagulant response of treatment doses of heparin
is highly variable [72] due to competition of a variable
number of plasma proteins with AT for heparin binding
and complex kinetics of heparin clearance. Thus, the peak
activity and duration of effect increase disproportionately
with increasing therapeutic doses (apparent half-life: 30 to
150 min) [73]. Thus, UFH therapy is monitored and the
dose is adjusted based on assay results. However, some
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UFH in the treatment of VTE may not always be needed.
Unmonitored, weight-adjusted subcutaneous heparin was
found to be as safe and effective as weight-adjusted
LMWH in a randomized trial of patients with VTE,
suggesting that aPTT monitoring of subcutaneous
heparin may not be needed [74]. The 9th edition of the
ACCP guidelines suggests that, for outpatients with
VTE treated with subcutaneous UFH, weight-adjusted
dosing should be used without monitoring rather than
fixed or weight adjusted dosing with monitoring [48].
In addition, a recent retrospective study has shown
that routine monitoring and heparin dose adjustment
may be unnecessary for patients receiving doses of at least
30 000 units/day [75], as for these patients, the mean pro-
portion of time with an aPTT of 0.2 anti-Xa IU/mL was
92%. The monitoring is also performed to prevent bleed-
ing but its utility is still controversial [76].
Global coagulation tests
Activated partial thromboplastin time The most com-
mon assay used to monitor heparin is the aPTT. Based
one prospective study performed in 1972 [77], an aPTT
ratio (reported therapeutic aPTT range divided by the
control value for the reagent) of 1.5 to 2.5 was adopted
as the therapeutic range for UFH. However, the defin-
ition of the control value is not well established. The
ACCP recommends against the use of a fixed aPTT tar-
get in seconds for any therapeutic indication of UFH
[73,78,79]. Each laboratory should determine this refer-
ence aPTT ratio range for each combination instrument/
reagent and for each lot of their cephalin. A French study
has recently shown a 3 to 8 fold aPTT increase for an
anti-Xa activity of 0.7 IU/mL (Table 1) [80]. Too sensi-
tive reagents do not allow a precise chronometric meas-
urement and therefore should not be used for UFH
monitoring [81,82]. In addition, mechanical end point
coagulometers showed greater sensitivity than optical
ones [83].
Similar reagent/instrument combinations showed less
variation in aPTT results than unlike combinations [82].
Using the same instrument model and same reagent lot
but performed in different laboratories, significant statis-
tical and clinical differences in the heparin therapeutic
range values are found, owing to variation in the individ-
ual plasma samples as well as pre-analytical and analytical
variables that can vary greatly between hospitals. It is thus
unacceptable for a large hospital network to determine
the therapeutic range of heparins at only one institution
for the whole network [84]. In addition, the procedure of
definition of therapeutic range is not defined and debated
[85-87]. In the study that established the therapeutic range
using the aPTT ratio, the range of aPTT ratios of 1.5-2.5corresponds to a heparin’s level of 0.3-0.7 IU/mL as deter-
mined by anti-Xa assay [88]. Thus, the more accurate
method to determine the aPTT ratios equivalent to 0.3-0.7
is to measure aPTT ratio and anti-Xa activity of patient
plasmas treated with different levels of anti-Xa. Spiking
a normal pool plasma with heparin solutions at differ-
ent concentrations doesn’t take the in vivo heparin me-
tabolism into account and leads to a more prolonged
aPTT in comparison to those of treated patients. The
regression relationship is then used to derive the range
of aPTT ratios equivalent to 0.3 to 0.7 IU/mL anti-Xa.
However, this calibration method may not enhance
inter-laboratory agreement in UFH monitoring [89]
and it should be noted that the evidence linking these
plasma heparin levels to the occurrence of bleeding or
thrombosis is of low quality [48].
Activated clotting time (ACT) Activated clotting time
is used to monitor higher doses of UFH given to pa-
tients undergoing percutaneous coronary intervention
(PCI) or cardiopulmonary bypass surgery, because at such
higher doses the aPTT becomes prolonged to the point of
becoming unmeasurable and unreliable. However, PCI
and cardiopulmonary bypass surgery induce major
hemostatic abnormalities [90-102]. The target ACT was
determined by historical papers in 1955 and 1978
[103,104]. The clinical relevance of this target ACT is
doubtful because it has never been validated in prospect-
ive studies and because ACT reagents and instruments
have changed over years. The ideal management of oral
anticoagulation during cardiopulmonary bypass [105,106]
and catheter ablation for AF [107-109] is still controver-
sial with a wide range of procedures available. During
AF ablation, it’s now recommended to achieve and
maintain an ACT of 300 to 400 seconds in order to re-
duce the risk of systemic thromboembolism [110].
However, the ACT is affected by a lot of pre-analytical
[111] and analytical variables [112,113]. Finally, target
ACT should be re-determined for the peri-procedural
use of NOACs for AF ablation. The management of
anticoagulation in adults and older children cannot be
extrapolated to neonates, due to physiological differ-
ences in hemostasis and the dilutional effects of cardio-
pulmonary bypass in infants [114].
Specific coagulation tests
Chromogenic anti-Xa assays Monitoring of UFH may
also be performed by anti-Xa activity measurement. The
UFH anti-Xa assay is based on the ability of heparin to
accelerate inhibition of a standard concentration of FXa in
the presence of antithrombin (AT). The test is performed
by diluting plasma in buffer, which may or may not con-
tain exogenous AT or dextran sulfate, and incubating with
Table 1 Key points about monitoring of unfractionated heparin, low molecular weight heparins and fondaparinux [78,162]
Indications Posology and route of administration Delay for blood sampling Anti-Xa activity (IU/mL) aPTT
Unfractionated heparin
Sodium heparin
-Prevention of clotting during
hemodialysis
Bolus of 1,000 - 5,000 IU followed by
1,000 - 2,000 IU per hour
The sampling is performed
whatever the time in case
of IV perfusion, preferably 4
to 6h after each dosage
variation.
0.3 to 0.7
1.5 to 3.0 – 8.0 the upper
limit of normal depending
on the reagent
-Cardiopulmonary bypass 300 units/kg intravenously, adjusted
thereafter to maintain the activated
clotting time (ACT) in the range
300-400 seconds
Calcium heparin
-Prevention of clotting during
hemodialysis
Loading dose of 1,000-5,000 units
followed by 1,000-2,000 units/hour
Part-time between 2 injections
(6h after injection for a 2
injections/day) or 4h after
injection for a 3 injections/day
-Cardiopulmonary bypass 300 units/kg intravenously, adjusted
thereafter to maintain the activated
clotting time (ACT) in the range
300-400 seconds
Low molecular weight heparins: 2 injections per day†
Enoxaparin
-DVT associated with or not PE 100 IU/kg/12 hours or 1mg/kg/12
hours - subcutaneous
3 to 4 hours after the
injection
1.2 (+- 0.17) IU/mL
Slightly prolonged
-Acute coronary syndrome
Dalteparin -Constituted DVT 100 to 120 IU/kg/12 hours –
subcutaneous
0.6 (+- 0.25) IU/mL (overdose
threshold 1.0 IU/mL)
Nadroparin -Unstable angina -Myocardial
infarction without Q wave
85 IU/kg/12 hours 1.0 (+- 0.2) IU/mL
Low molecular weight heparins: 1 injection per day†
Tinzaparin -Constituted DVT 175 IU/kg/24h 4 to 6 hours after the
injection
0.87 (+- 0.15) IU/mL (overdose
threshold: <1.5 IU/mL)
Prolonged
-PE
Nadroparin -Constituted DVT 171 IU/kg/24h 1.34 (+- 0.15) IU/mL (overdose
threshold: <1.8 IU/mL)
Slightly prolonged
Fondaparinux
Fondaparinux
-Constituted DVT In patients with DVT or PE, dosing was
determined by patient weight, with
either 5 mg (weight <50 kg), 7.5 mg
(weight 50–100 kg), or 10 mg
(weight >100 kg) administered/24hours.
2 to 3 hours after
administration
The mean peak steady state
concentrations for were
1.20–1.26 mg/L
Not prolonged
-PE
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Table 1 Key points about monitoring of unfractionated heparin, low molecular weight heparins and fondaparinux [78,162] (Continued)
-Acute coronary syndrome 2.5 mg/24 hours 2 to 3 hours after administration Healthy males receiving a single
2.5 mg dose of fondaparinux
had an average peak steady state
(3 hours) concentration of
0.39–0.5 mg/L
†In neonates or children receiving therapeutic LMWH either once or twice daily the drug should be monitored to a target anti-Xa of 0.5–1.0 IU/mL in a sample taken 4–6 hours or 0.5–0.8 IU/mL in a sample taken 2–6
hours after subcutaneous injection [157].
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ous AT or dextran sulphate may overestimate the actual
in vivo activity of UFH, LMWH or fondaparinux in pa-
tients with excess plasma proteins or deficient levels of
AT [85,115]. The phenomenon is also encountered in
neonates since antithrombin function is significantly de-
creased in neonates, and by supplementing the assay with
exogenous antithrombin there is a direct disturbance of
the physiological scenario [116]. The advantage of anti-
Xa activity over aPTT is to not be influenced by vari-
ation of inflammatory proteins like factor VIII or fi-
brinogen, by factor deficiencies and lupus anticoagulant.
The anti-Xa activity is also preferred to aPTT in children
less than 1-year-old [117], in case of prolonged aPTT
before treatment initiation and for patients with im-
portant inflammatory syndrome affecting aPTT [85].
When the baseline prolongation of aPTT is due to
lupus anticoagulant, an insensitive reagent (giving a
normal baseline aPTT) should be used [29]. Qualitative
or quantitative AT deficiency should evoke a biological
or clinical heparin resistance, with an abnormally short
aPTT and a weak anti-Xa activity (when measured by a
method without in vitro addition of antithrombin). There
are differences between commercially available methods
but the clinical relevance seems to be limited [85].
The frequency of testing and the therapeutic range are
mentioned in Table 1 [80].
Finally, a recent large retrospective cohort analysis has
shown that patients with disproportionate prolongation
of aPTT relative to anti-Xa activity did have a highest
30-day mortality and a highest risk of bleeding. If these
data are confirmed prospectively, it may be useful to
measure both aPTT and anti-Xa [118].Low molecular weight heparins
Low molecular weight heparins show a more predictable
anticoagulant response than UFH because the shorter
heparin chains exhibit lowered affinity for heparin binding
proteins in the plasma. Moreover, thanks to reduced bind-
ing to the endothelium, LMWHs have a longer half-life
than UFH, and the half-life is dose-independent. LMWHs
with longer chain lengths have shorter half-lives than
LMWHs with shorter chain length, and therefore are less
prone to accumulation. LMWHs are cleared by the kidneys
and therefore, can accumulate in the plasma of patients
with impaired renal function. Typically, LMWHs are given
in fixed- or weight-adjusted doses without monitoring.
ACCP guidelines recommend against routine coagulation
monitoring (grade 1C) [88]. Indeed, data on the correlation
between anti-Xa levels and bleeding risk are controversial
[78]. A randomized controlled trial comparing monitored
versus unmonitored dalteparin therapy for the treatment
of VTE showed no benefit of monitoring [119]. In addition,routine monitoring of anti-Xa levels is costly and incon-
venient for physicians, patients and laboratory.
LMWHs may produce some prolongation of the aPTT
(from 0.6 IU/mL of LMWH [81]), but their effect on the
aPTT is less than that of UFH. Thus, aPTT cannot be
used for monitoring [73]. Therefore and accordingly, the
measurement of the anti-Xa activity is the recommended
test [73]. Recommendations advice to monitor the in-
tensity of anticoagulation via the measurement of peak
anti-Xa activity levels with various target ranges de-
pending on the LMWH preparation and the frequency
of dosing (Table 1) [78,120]. One limitation is that
thresholds have not always been validated in terms of
clinical outcomes [80].
Since every LMWH is different, LMWHs monitoring
requires calibration towards the specific LMWH used
for therapy [29]. Other limitations of anti-Xa activity
measurement include a poor comparability between com-
mercially available anti-Xa chromogenic assays [121,122],
substantial inter-laboratory variation in results [81] and
poor correlation to antithrombotic efficacy [123]. In con-
trast to what is generally assumed, the inter-individual
variation of the in vitro pharmacodynamics response is
equally higher for UFH and any LMWH, (i.e. 25%) when
measured by a global assay like thrombin generation assay
[124,125].
Thus, monitoring may be used in obese patients, in
those with renal insufficiency or with cirrhosis [126],
when therapeutic doses of LMWH are required during
pregnancy and in neonates and infants [102].
Cirrhosis
The anti-Xa assay cannot be used in patients with liver
disease to monitor AT-dependent anticoagulant drugs as
it underestimated drug levels [126-129]. This underesti-
mation is due to the acquired AT deficiency in these
patients [130]. The addition of exogenous AT corrects
the drug level. Dose escalations suggested by a low anti-
Xa level will potentially lead to a substantial bleeding risk
[126]. Clinical trials on the monitoring, efficacy and safety
of heparins are urgently required to improve antithrom-
botic therapy in patients with cirrhosis.
Pregnancy
The usefulness to monitor the intensity of therapeutic
anticoagulant with LMWH during pregnancy is still con-
troversial. Recommendations vary significantly among
recent guidelines [131-134]. For a given dose of LMWH,
anti-Xa levels are lower in pregnancy than in the non-
pregnant state. Lower levels of anti-Xa levels in pregnant
patients receiving therapeutic doses of tinzaparin are
observed later in gestation [135,136]. These observations
suggest that higher doses or more frequent dosing may
be required to achieve a desired anticoagulant effect among
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case series of pregnant women requiring anticoagulation
(tinzaparin at a daily dose of 175 IU/kg) therapy during
pregnancy has shown that weight based anticoagulant
therapy did not achieve the target range of anticoagulation
throughout pregnancy with more than 50% patients
showing subtherapeutic levels. Thus it does not seem
that adjusting doses for increasing pregnancy weight is
sufficient [137]. Further studies in this field in urgently
are required.
Obese patients
Obesity is an important risk factor for venous thrombo-
embolism [138]. Standard fixed doses are suboptimal in
obese patients [139-141]. Thus, ACCP guidelines recom-
mend weight-based dosing in obese patients receiving
LMWH prophylaxis or treatment (grade 2C) [88].
In a meta-analysis that included data on 921 patients
with a BMI >30, there was no excess in the rate of major
bleeding over that observed in non-obese patients who
received LMWH in doses adjusted by total body weight
[78]. For thromboprophylaxis with fixed-dose enoxaparin
and nadroparin, there is a strong negative correlation
between total body weight and anti-Xa levels in obese
patients [78,139]. In contrast, prescribing approximately
0.5 mg/kg of enoxaparin daily results in anti-Xa levels
that are within or near target levels [142]. In a recent large
prospective study on 3928 morbidly obese inpatients,
high-dose thromboprophylaxis approximately halved the
odds of symptomatic VTE, with no increased risk of
bleeding [143]. In conclusion, further studies regarding
optimal doses for obese patients with anti-Xa factor
measurements are still required.
Several renal insufficiency
Appropriate dosing of LMWHs in patients with renal in-
sufficiency is less clear. There is an inverse relationship
between CRCL and anti-Xa levels [78,144,145] and the
risk of bleeding complications with LMWHs is higher in
patients with impaired renal function [78,146,147]. Severe
renal insufficiency (CRCL lower than 30 mL/min) is a
contra-indication of randomized controlled trials evaluat-
ing efficacy and safety of LMWHs. In such patients, UFH
is, in most cases, a better choice than LMWHs despite
numerous drawbacks [148], as UFH is less dependent on
renal function. The data on accumulation with LMWHs
other than enoxaparin is limited. When used in full thera-
peutic doses, nadroparin and dalteparin clearance, but not
tinzaparin clearance, was shown to be correlated with
CrCL [148-151]. The apparent difference in tinzaparin
clearance in patients with severe renal insufficiency may
reflect metabolism by hepatic mechanisms, possibly due
to the higher molecular weight of tinzaparin compared
with other LMWHs. Two approaches are consideredto optimize the use of LMWHs in the elderly: anti-
Xa monitoring or empiric LMWHs dose reduction.
However, it is still debated whether there is a clear
benefit in anti-Xa monitoring regarding LMWHs effi-
cacy and safety outcomes, especially in patients with renal
impairment [120,152,153]. Alternatively, empirically redu-
cing the dose to 50 % of the recommended dose has also
been proposed by ACCP with a low grade of recommen-
dation for enoxaparin in patients with ACS or VTE with
severe renal impairment [78]. However, the empirical re-
duction of the initial enoxaparin dose without systematic
monitoring could lead to an anti-Xa peak level below 0.5
IU/mL, leading to an increase of the thrombotic risk
[154]. No specific recommendations have been made for
other LMWH preparations given the lack of sufficient
data [78,155]. When given in prophylactic doses, LMWHs
has not been shown to increase the risk of bleeding com-
plications, irrespective of the degree of impairment of
renal function [78].Neonates and infants
The variability in age-related pharmacokinetic parameter
estimates (clearance, volume of distribution and half-life)
leads to a different pharmacodynamics profile for antico-
agulants in children in comparing to adults [116,156]. The
9th edition of the ACCP guidelines recommend that in
neonates or children receiving therapeutic LMWHs either
once or twice daily the drug should be monitored to a tar-
get anti-Xa of 0.5–1.0 IU/mL in a sample taken 4–6 hours
or 0.5–0.8 IU/mL in a sample taken 2–6 hours after
subcutaneous injection [157]. There is a need for robust
pharmacodynamics models in pediatric practice. The
current recommendations regarding anticoagulant dosing
or laboratory monitoring in children are simply extrapo-
lated from adult evidence and are not based on appropri-
ately robust levels of evidence [156]. Therapeutic ranges
are not well correlated with clinical outcomes and assays
are not standardized. In 2012, a position paper from the
Perinatal and paediatric haemostasis subcommittee of the
scientific and standardization Committee of the Inter-
national Society on Thrombosis and Haemostasis (ISTH),
recommends a step-wise approach to the generation of
this evidence [146]. A recent study has shown that enoxa-
parin dose titration to achieve therapeutic anti-Xa levels
may be affected by assay variability. Attempts to titrate
to target anti-Xa values may result in significant dose
variation that may or may not benefit pediatric patient
care. Neonates or children with normal renal function
may be safely treated with weight-based age-appropriate
standard dosing without monitoring. Therefore, these au-
thors suggest that a prospective, multicenter, randomized
clinical trial comparing the safety and efficacy of exona-
parin weight-based dosing with and without anti-Xa dose
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[158].Fondaparinux
Fondaparinux is cleared only by renal function. Biological
monitoring is not recommended. Anti-IIa assay and aPTT
are not recommended as they have only a very low sensi-
tivity to fondaparinux [159-161]. Anti-Xa measurement
should be performed with appropriate calibration allowing
results expression in ng/mL. Dose tailoring is not rec-
ommended according to anti-Xa results. The target
ranges (2 to 3 days after injection) are in mean 1.41
mg/mL (0.97-1.92 for 5th and 95th percentiles). The
through values are in mean 0.52 mg/mL (0.24-0.95 for
the 5th and 95th percentile) for a patient receiving 7.5 mg
once a day [162]. No specific data have been published in
the very elderly receiving fondaparinux at curative dose
[163]. Healthy males receiving a single 2.5 mg dose of
fondaparinux had an average peak steady state (3 hours)
concentration of 0.39–0.5 mg/L [164]. In patients with
deep vein thrombosis or pulmonary embolism, dosing
was determined by patient weight, with either 5 mg
(weight <50 kg), 7.5 mg (weight 50–100 kg), or 10 mg
(weight >100 kg) administered. The mean peak steady
state concentrations for all three-weight classes were
1.20–1.26 mg/L [164,165].Non-vka oral anticoagulants
Non-VKA Oral Anticoagulants (NOACs) have been
developed to counter one of the main disadvantages of
VKA treatment: the requirement of regular monitoring.
However, even if these treatments are given without
dose adjustments, several situations or populations may
require an assessment of the intensity of anticoagulation
(See the “Summary of patients/situations that could re-
quire a drug tailoring” section). Moreover, a recent investi-
gation made by the BMJ revealed that the marketing
authorization holder of dabigatran etexilate, marketed
under the brand name of Pradaxa® in Europe, found that if
the plasma levels of the drug were measured and the dose
was adjusted accordingly major bleeds could be reduced
by 30-40% compared with well controlled warfarin [166].
Similar information was also provided in a study evaluat-
ing the effect of dabigatran plasma concentrations and
patient characteristics on the frequency of ischemic stroke
and major bleeding in atrial fibrillation patients in the
RE-LY trial [167]. Thus, the “one dose fits all” marketing
slogans behind the approval of these drugs proved to
be an illusion, for at least one of these compounds.
The drug companies of the other NOACs do not yet
provide such information. However, the collection, ana-
lyses and distribution of similar data are of particular
importance since we cannot afford to deprive us ofthe opportunity to improve the safety/efficacy profile
of these drugs by implementing risk minimization mea-
sures, if feasible.
Summary of patients/situations that could require a drug
tailoring
Even if NOACs are presented as having a predictable
pharmacodynamics and pharmacokinetics, several patients
or situation could require an assessment of the degree of
anticoagulation and probably a drug tailoring.
The clinical situations include: recurrence of thrombosis
or bleeding, before urgent surgery or procedure (with last
administration in the last 24 h or more if CRCL <50mL/
min), before fibrinolytic therapy of acute ischemic stroke, in
case of bridging therapy, in case of cardioversion and in the
setting of dual or triple antithrombotic therapy, such as in
the patient with AF undergoing a percutaneous coronary
intervention, when dual platelet inhibitors may be added
to NOACs, given that such patients represent a complex
management problem.
In addition, several patterns in patient status could also
require an assessment of the responsiveness at the individual
level. This includes patients with risk factors for NOACs
accumulation or too low levels (i.e. drug-drug interactions as
with frequently used medication like amiodarone and verap-
amil), patients with extreme body weight (<50 kg or >110 kg),
patients with hepatic impairment, patients with renal impair-
ment (in case of progressive decrease of renal function but
also in acute decrease during dehydration, antibiotics admin-
istration, …), in case of comorbidities or in elderly patients.
How to accurately measure plasma drug concentrations?
In this part of the manuscript, we review the different
routine coagulation tests that could be used to estimate
the intensity of anticoagulation in patients treated with
dabigatran etexilate (the pro-drug of dabigatran, a direct
thrombin inhibitor) and with rivaroxaban or apixaban,
two direct factor Xa inhibitors. More specific assays used
to accurately estimate plasma drug concentrations are also
presented.
Global coagulation tests
Dabigatran: activated Partial Thromboplastin Time
The recent recommendation of the Subcommittee of
Control of Anticoagulation of the Scientific and Stand-
ardisation Committee of the ISTH, mentions that the
aPTT using most available reagents can be used to deter-
mine the relative intensity of anticoagulation due to dabi-
gatran. However, they state that aPTT should not be used
to quantify the drug plasma concentration. They add that
each laboratory should be aware of the sensitivity of their
aPTT assays to dabigatran and this can be achieved using
commercially available plasma calibrants [168]. However,
it is unknown if specific dabigatran calibrants, used out of
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that could reflect accurately the impact of dabigatran in
plasma from patient’s sample, since aPTT is affected by
numerous pre-analytical and biological variables.
It is stated in the EU-SmPC that when dabigatran was
used for the prevention of stroke in NVAF with a bid
dosing regimen, an aPTT ratio greater than 2xULN (or
an aPTT prolongation of about 80 seconds) at trough
(10-16 h after the previous dose) reflected the 90th per-
centile of observations (i.e. 200 ng/mL at Ctrough) and is
considered to be associated with a higher risk of bleeding
[169]. However, studies revealed that the inter-reagent
variability prevents using an aPTT of about 80 seconds as
reflecting plasma dabigatran concentration of 200 ng/mL
[170] (Figure 1). Similar observations have been demon-
strated for the threshold proposed in VTE prevention
regarding the bleeding risk [170]. Moreover, recent findings
revealed that in addition to the inter-reagent variability, the
different combinations between reagents and coagulometers
increased further this variability [171]. Therefore, laboratories
should be aware about the sensitivity of their aPTT reagents
towards dabigatran assessed with homemade calibrants using
local normal pooled plasma spiked with dabigatran.
Thus, aPTT has limited sensitivity depending on the
reagent and is not suitable for precise quantification of
the anticoagulant effect for several reasons. First, the
aPTT is affected by pre-analytical and biological variables
[172,173]. Secondly, a prolonged aPTT is not strongly
predictive of hemorrhage and patients may experience
bleeding while displaying a normal aPTT [173-175] and
finally, the dose-response is not linear, precluding the
possibility to differentiate minor versus major overdoses
(Figure 1).Figure 1 Impact of dabigatran on several aPTT reagents.Rivaroxaban: Prothrombin Time/INR The Subcom-
mittee of Control of Anticoagulation of the Scientific and
Standardization Committee of the ISTH mentions that PT
(with a sensitive reagent) can be used to determine the
relative intensity of anticoagulation in emergency situation
when required, but should not be used to quantify drug
plasma concentrations [168]. However, PT results of
samples from patients treated with rivaroxaban cannot
be translated to INR values since INR was developed to
normalize PT in patients treated by VKA thanks to the
International Sensitivity Index (ISI) specifically deter-
mined for VKA therapy.
In-vitro studies reported a large PT reagents variability
and, as for dabigatran and the aPTT, the different combi-
nations between PT reagents and coagulometers increased
further this variability [160,171,176-178] suggesting that
laboratories should be aware about the sensitivity of their
own reagent towards rivaroxaban (Figure 2). The Sub-
committee of Control of Anticoagulation of the Scientific
and Standardization Committee of the ISTH support this
statement [168]. Nevertheless, one weakness of this ap-
proach is that commercially available calibrants are la-
belled to be used with their corresponding chromogenic
anti-Xa assays. Therefore, similarly to dabigatran and the
aPTT, the quality and the accuracy of these calibrants for
the calibration of PT reagents are not warranted. In
addition, an ex-vivo study revealed a poor correlation be-
tween calibrated-PT and measured rivaroxaban plasma
concentration [179].
Therefore, depending on the reagent, PT must not be
used to estimate rivaroxaban concentrations in plasma
and poorly reflects the intensity of anticoagulation due to
rivaroxaban. The poor sensitivity, the important variabilityFigure 2 Impact of rivaroxaban on several PT reagents.
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tients’ plasma samples preclude the use of PT to estimate
rivaroxaban plasma concentration.Apixaban: Prothrombin Time/INR or modified PT
As stated for rivaroxaban, INR must not be used for the
assessment of apixaban while PT, either expressed in
seconds or as ratio, is not sensitive enough to ensure an
accurate quantitative measurement of apixaban [180-182].
Moreover, depending on the reagent, PT may be normal
with therapeutic concentration of the drug [182,183]. For
the most sensitive reagents it may only inform the clin-
ician if the patient is taking the drug. This inter-reagent
variability (Figure 3) prevents valid recommendations
of cut-offs in seconds associated with a bleeding risk
applicable to all reagents [181]. In addition, drugs or
hematologic abnormalities affecting at least one factor
assessed by PT could bias the conclusions. We definitively
do not recommend PT to estimate plasma concentration
of apixaban. During the early clinical development of a
series of novel factor Xa inhibitors, a modified PT (mPT)
assay was developed in which calcium chloride (CaCl2)
was added to the thromboplastin reagent in order to pro-
long clotting times and, hence, increase the sensitivity of
the dose–response curve for the direct factor Xa inhibitor
[184]. Thus, mPT method could be used for the assessment
of the pharmacodynamics activity, but the limitations
highlighted previously for PT might remain valid and the
inter-reagent and inter-individual variability must be
assessed. With further development and standardization,
this assay could provide a potential option [181,184].Figure 3 Impact of apixaban on several PT reagents.Specific coagulation tests
Dabigatran: dilute Thrombin Time (dTT): Ecarin
Clotting Time (ECT) and Ecarin Chromogenic Assay
(ECA) Thrombin Time (TT) was demonstrated to be
too sensitive towards dabigatran [170,185] and led to
the development of a calibrated diluted thrombin time
(dTT) using dabigatran standards to calculate the
plasma concentrations. Hence, the CE-marked Hemoclot
Thrombin Inhibitor® (HTI) was developed and has
been proposed as a rapid, standardised and calibrated
assay to determine plasma concentrations of dabiga-
tran [170,185-187]. The coagulation test is based on
the addition of highly purified thrombin in the α-form
in plasma samples pre-diluted in physiological serum
(1/8 ratio) and normalized with a defined amount of
normal pooled plasma. By diluting plasma samples, the
test is less sensitive to dabigatran and allows the quantita-
tion of dabigatran concentration from 50 to 500 ng/mL. It
is fully automatable and has been adapted to different coa-
gulometers in order to be easily implemented in laborator-
ies. Several studies showed that HTI highly correlates with
dabigatran plasma concentrations measured by LC-MS/
MS in patient’s plasma [185,186,188,189]. Nevertheless,
for the accurate determination of dabigatran plasma con-
centrations below 50 ng/mL, the more sensitive LC-MS/
MS method is still required [186,188].
The ECT assay provides a direct measure of the activity
of direct thrombin inhibitors. Ecarin is a snake venom ex-
tracted from Echis carinatus. Ecarin cleaves prothrombin
to form meizothrombin, an active effector able to trans-
form fibrinogen to fibrin. Meizothrombin is sensitive to
direct thrombin inhibitors (DTIs) but is unaffected by
heparin and its derivatives as well as by antithrombin
[190]. While development of commercial kits may im-
prove the practicality of this test, these kits have not
been standardised or validated with dabigatran [185].
For these reasons, ECT cannot be recommended for
emergency monitoring of anticoagulant effects. More-
over, ECT is not widely available and is known to have
inter-lot variability indicating that calibration is also
required with this test [170].
Recently, the ECA, the chromogenic variant of ECT,
has been specifically developed to accurately estimate
the plasma concentration of dabigatran and other DTIs
in plasma. In this test, ecarin converts an excess of ex-
ogenous prothrombin added in the diluted plasma sample
to form meizothrombin. The cleavage of the chromo-
genic substrate by the residual meizothrombin released
p-nitroaniline (pNA) that can be measured at 405nm.
The quantity of pNA generated is inversely proportional
to the quantity of DTIs in the plasma. For dabigatran
measurements, the test is calibrated with standard cali-
brants and provides a lower limit of quantitation similar
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yet approved [188,189,191].
Rivaroxaban: chromogenic anti-Xa assays Thanks to
specific calibrants and controls containing a defined
amount of rivaroxaban, a dedicated chromogenic anti-
Xa assay has been proven to accurately estimate plasma
rivaroxaban concentrations >30 ng/mL [179]. Several
chromogenic anti-Xa assays are available on the market,
however, only some of them are labelled to ensure the
quantitation of rivaroxaban plasma concentrations. It is
therefore important to work on specific coagulation plat-
forms where it was previously found that the mean CV is
lower in the inter-laboratory setting [192].
However, taking into account the lower sensitivity
of chromogenic assays compared to LC-MS/MS and
the variability of coagulation analysers that may further
increase the imprecision at the lowest concentrations,
detection and quantitation of lower levels (<30 ng/mL) in
rivaroxaban treated patients still requires LC-MS/MS ana-
lyses [179,193]. Consequently, the LC-MS/MS is required
for quantification of very low to moderate rivaroxaban
concentrations (3 to 30 ng/mL) in clinical samples.
Apixaban: chromogenic anti-Xa assays Due to their
good sensitivity towards the inhibition of FXa by apixa-
ban, chromogenic anti-Xa assays calibrated with specific
apixaban calibrants could estimate plasma drug concen-
trations [181,183]. Patients of the APPRAISE-1 study had
participated in a PK/PD study suggesting that apixaban-
mediated anticoagulant effect can be detected using a
standard laboratory chromogenic anti-Xa assay with either
LMWH or apixaban calibrants [194]. However, the au-
thors failed to mention that the chromogenic anti-Xa
assay tended to underestimate the plasma drug concentra-
tion when comparing plasma apixaban concentrations es-
timated by the calibrated STA®-Rotachrom® and the true
plasma concentration measured by LC-MS/MS [194].
Thus, further studies are required with validated calibrants
to compare dedicated calibrated chromogenic anti-Xa as-
says with LC-MS/MS in real-life patients treated by Eli-
quis®. As for rivaroxaban, it seems to be preferable to
work on specific coagulation platforms to reduce the
inter-laboratory CV [183,195].
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